The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials

[1]  M. Mack,et al.  A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19 , 2022, American journal of respiratory and critical care medicine.

[2]  K. Majidzadeh-A,et al.  Human placenta-derived mesenchymal stem cells transplantation in patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 (phase I clinical trial): safety profile assessment , 2022, Stem Cell Research & Therapy.

[3]  A. Sedaghat,et al.  Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial , 2022, Stem Cell Research & Therapy.

[4]  G. Perkins,et al.  Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial , 2022, Trials.

[5]  D. Annane,et al.  Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial , 2022, Critical Care.

[6]  R. Petterle,et al.  Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial , 2021, Stem Cell Research & Therapy.

[7]  Bo Zhang,et al.  Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial , 2021, eBioMedicine.

[8]  D. Allan,et al.  Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol , 2021, Systematic Reviews.

[9]  I. Liem,et al.  Umbilical cord mesenchymal stromal cells as critical COVID‐19 adjuvant therapy: A randomized controlled trial , 2021, Stem cells translational medicine.

[10]  C. Ricordi,et al.  Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients. , 2021, European review for medical and pharmacological sciences.

[11]  M. Matthay,et al.  Mesenchymal stromal cells reduce evidence of lung injury in patients with ARDS , 2021, JCI insight.

[12]  J. Granados-Arriola,et al.  Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19 , 2021, Aging and disease.

[13]  R. Xu,et al.  Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial , 2021, Signal Transduction and Targeted Therapy.

[14]  M. Soleimani,et al.  Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series , 2021, Stem cell research & therapy.

[15]  Daniel S. Chertow,et al.  Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update , 2021, Critical care medicine.

[16]  Lanjuan Li,et al.  Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial , 2021, Clinical and translational medicine.

[17]  J. Rubio,et al.  Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial , 2021, Trials.

[18]  A. Marttos,et al.  Umbilical cord mesenchymal stem cells for COVID‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial , 2021, Stem cells translational medicine.

[19]  E. Karaoz,et al.  The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial , 2021, Cell transplantation.

[20]  Dawei Wang,et al.  Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study , 2020, Critical Care.

[21]  Zhou Lixin,et al.  Mesenchymal Stromal Cells Attenuate Infection-Induced Acute Respiratory Distress Syndrome in Animal Experiments: A Meta-Analysis , 2020, Cell transplantation.

[22]  Lixin Zhou,et al.  The efficacy of mesenchymal stromal cell-derived therapies for acute respiratory distress syndrome—a meta-analysis of preclinical trials , 2020, Respiratory Research.

[23]  V. Sengupta,et al.  Exosomes Derived From Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. , 2020, Stem cells and development.

[24]  Changming Niu,et al.  Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells , 2020, Stem Cell Research & Therapy.

[25]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[26]  A. Marttos,et al.  Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). , 2020, CellR4-- repair, replacement, regeneration, & reprogramming.

[27]  J. Silvestri,et al.  Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants. , 2019, The Journal of pediatrics.

[28]  J. Laffey,et al.  Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury. , 2019, American journal of respiratory and critical care medicine.

[29]  A. Randolph,et al.  The acute respiratory distress syndrome. , 1996, New England Journal of Medicine.

[30]  M. Exline,et al.  Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. , 2019, The Lancet. Respiratory medicine.

[31]  D. Brodie,et al.  Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome , 2018, The New England journal of medicine.

[32]  O. Gajic,et al.  Fifty Years of Research in ARDS. Is Acute Respiratory Distress Syndrome a Preventable Disease? , 2017, American journal of respiratory and critical care medicine.

[33]  C. Rebelatto,et al.  Combined Bone Marrow‐Derived Mesenchymal Stromal Cell Therapy and One‐Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial , 2016, Stem cells translational medicine.

[34]  Anders Larsson,et al.  Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. , 2016, JAMA.

[35]  Arthur S Slutsky,et al.  Driving pressure and survival in the acute respiratory distress syndrome. , 2015, The New England journal of medicine.

[36]  B. Thompson,et al.  Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. , 2015, The Lancet. Respiratory medicine.

[37]  K. Delucchi,et al.  Design and implementation of the START (STem cells for ARDS Treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal cells for the treatment of moderate-severe acute respiratory distress syndrome , 2014, Annals of Intensive Care.

[38]  Hye Soo Yoo,et al.  Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. , 2014, The Journal of pediatrics.

[39]  Q. Shu,et al.  Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study , 2014, Respiratory Research.

[40]  D. Stewart,et al.  Effects of Mesenchymal Stem Cell Therapy on the Time Course of Pulmonary Remodeling Depend on the Etiology of Lung Injury in Mice , 2013, Critical care medicine.

[41]  R. Casaburi,et al.  A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. , 2013, Chest.

[42]  Arthur S Slutsky,et al.  Acute Respiratory Distress Syndrome The Berlin Definition , 2012 .

[43]  D. Rowlands,et al.  Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury , 2012, Nature Medicine.

[44]  M. Reitz,et al.  Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling. , 2011, Stem cells and development.

[45]  M. Matthay,et al.  Antibacterial Effect of Human Mesenchymal Stem Cells Is Mediated in Part from Secretion of the Antimicrobial Peptide LL‐37 , 2010, Stem cells.

[46]  Jae W. Lee,et al.  Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung , 2009, Proceedings of the National Academy of Sciences.

[47]  A. Uccelli,et al.  Mesenchymal stem cells in health and disease , 2008, Nature Reviews Immunology.

[48]  Rafael Fernández,et al.  A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. , 2006, American journal of respiratory and critical care medicine.

[49]  G. Sukhikh,et al.  Mesenchymal Stem Cells , 2002, Bulletin of Experimental Biology and Medicine.

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  Ralf Huss,et al.  Isolation of Primary and Immortalized CD34− Hematopoietic and Mesenchymal Stem Cells from Various Sources , 2000, Stem cells.

[52]  C. Carvalho,et al.  Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. , 1998, The New England journal of medicine.